Stryker (NYSE:SYK) was upgraded by equities researchers at Robert W. Baird from a “neutral” rating to an “outperform” rating in a report released on Thursday, November 16th, Marketbeat Ratings reports. The brokerage presently has a $173.00 target price on the medical technology company’s stock, up from their previous target price of $161.00. Robert W. Baird’s price objective indicates a potential upside of 13.55% from the company’s previous close.
Several other research analysts have also commented on the company. ValuEngine raised Stryker from a “hold” rating to a “buy” rating in a research report on Tuesday, November 14th. Needham & Company LLC reaffirmed a “hold” rating on shares of Stryker in a research report on Friday, November 3rd. Oppenheimer set a $156.00 target price on Stryker and gave the company a “hold” rating in a research report on Monday, October 30th. Cowen set a $166.00 target price on Stryker and gave the company a “buy” rating in a research report on Sunday, October 29th. Finally, Barclays upped their target price on Stryker from $137.00 to $148.00 and gave the company an “underweight” rating in a research report on Friday, October 27th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and thirteen have issued a buy rating to the stock. Stryker presently has a consensus rating of “Hold” and an average price target of $152.10.
Stryker (SYK) traded down $3.51 on Thursday, hitting $152.36. The stock had a trading volume of 1,351,039 shares, compared to its average volume of 1,182,374. The company has a market cap of $57,020.00, a price-to-earnings ratio of 24.70, a price-to-earnings-growth ratio of 2.45 and a beta of 0.78. The company has a current ratio of 2.37, a quick ratio of 1.61 and a debt-to-equity ratio of 0.63. Stryker has a 52-week low of $111.22 and a 52-week high of $160.62.
Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, October 26th. The medical technology company reported $1.52 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.50 by $0.02. The firm had revenue of $3.01 billion during the quarter, compared to analyst estimates of $2.97 billion. Stryker had a return on equity of 24.11% and a net margin of 14.67%. The business’s revenue for the quarter was up 6.1% compared to the same quarter last year. During the same period in the previous year, the company posted $1.39 EPS. research analysts forecast that Stryker will post 6.47 earnings per share for the current fiscal year.
In other news, insider Lonny J. Carpenter sold 5,000 shares of the stock in a transaction dated Friday, November 3rd. The stock was sold at an average price of $155.34, for a total value of $776,700.00. Following the transaction, the insider now directly owns 83,207 shares of the company’s stock, valued at $12,925,375.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.40% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently modified their holdings of SYK. Acrospire Investment Management LLC purchased a new stake in shares of Stryker in the second quarter worth about $111,000. Bollard Group LLC boosted its stake in shares of Stryker by 0.4% in the second quarter. Bollard Group LLC now owns 832 shares of the medical technology company’s stock worth $115,000 after buying an additional 3 shares during the last quarter. Motco boosted its stake in shares of Stryker by 50.7% in the second quarter. Motco now owns 826 shares of the medical technology company’s stock worth $115,000 after buying an additional 278 shares during the last quarter. San Francisco Sentry Investment Group CA boosted its stake in shares of Stryker by 47.8% in the third quarter. San Francisco Sentry Investment Group CA now owns 1,005 shares of the medical technology company’s stock worth $143,000 after buying an additional 325 shares during the last quarter. Finally, Bruderman Asset Management LLC purchased a new stake in shares of Stryker in the second quarter worth about $150,000. Hedge funds and other institutional investors own 74.97% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Stryker (SYK) Stock Rating Upgraded by Robert W. Baird” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/12/04/stryker-corporation-syk-upgraded-at-robert-w-baird.html.
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.